RHHBY - Roche Holding AG

Other OTC - Other OTC Delayed Price. Currency in USD
30.90
+0.27 (+0.88%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close30.63
Open30.79
Bid0.00 x 0
Ask0.00 x 0
Day's Range30.63 - 30.92
52 Week Range28.05 - 36.82
Volume1,418,474
Avg. Volume1,803,114
Market Cap215.609B
Beta0.54
PE Ratio (TTM)21.76
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.03 (3.37%)
Ex-Dividend Date2017-03-15
1y Target EstN/A
Trade prices are not sourced from all markets
  • Cancer Space Update: Roche, Pfizer & Regeneron Make Data Presentations
    Zacksyesterday

    Cancer Space Update: Roche, Pfizer & Regeneron Make Data Presentations

    Several presentations at the annual meeting of the American Society of Hematology grab headlines in the cancer space.

  • Pharma Stock Roundup: Teva Announces Major Job Cuts, Lilly Provides 2018 Outlook
    Zacksyesterday

    Pharma Stock Roundup: Teva Announces Major Job Cuts, Lilly Provides 2018 Outlook

    This week's pharma sector highlights include ASH data, Teva's restructuring announcement and Lilly's (LLY) 2018 outlook.

  • Roche/AbbVie Report Positive Phase III Results on Venclexta
    Zacks3 days ago

    Roche/AbbVie Report Positive Phase III Results on Venclexta

    Roche (RHHBY) announced positive results from a pivotal phase III study, MURANO, evaluating Venclexta plus Rituxan compared to bendamustine plus Rituxan (BR) for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL).

  • AbbVie Makes Progress on Quest to Diversify
    Motley Fool4 days ago

    AbbVie Makes Progress on Quest to Diversify

    AbbVie and Roche Holdings reported solid data for a drug that could have multibillion-dollar potential.

  • Why Exelixis, Inc. Stock Is Bound to Soar Higher in the Long Run
    InvestorPlace4 days ago

    Why Exelixis, Inc. Stock Is Bound to Soar Higher in the Long Run

    The former is used in combination with Roche’s Zelboraf as a treatment for advanced melanoma. Also, EXEL stock holders are looking at first-line approval for Cabometyx for hepatocellular carcinoma (a type of liver cancer) as potential for significant upside. EXEL retains marketing rights for Cabometyx in the U.S. and it has licensed marketing rights to Takeda Pharmaceutical Co Ltd (ADR) (OTCMKTS:TKPYY) in Japan and France-based Ipsen S A/S ADR (OTCMKTS:IPSEY) outside the U.S. and Japan.

  • Roche Reports Positive Data from Tecentriq Combination Study
    Zacks5 days ago

    Roche Reports Positive Data from Tecentriq Combination Study

    Roche reported positive data from a combination study of Tecentriq and Avastin in metastatic renal cell carcinoma patients.

  • Forbes5 days ago

    Roche's Fight With Pfizer May Be Just The Beginning

    Roche recently sued Pfizer to block the latter’s biosimilar (generic version) for Herceptin- a cancer biologic that earned $2.5 billion in sales in the U.S. for Roche in 2016. The fight is unlikely to stop there for Roche, as it has a lot more at stake.

  • Reuters5 days ago

    Merck raises stakes in lung cancer as rivals close in

    Merck & Co Inc, maker of the only immunotherapy approved for patients newly-diagnosed with the most common type of lung cancer, could solidify its lead by playing the long game, even as rivals edge closer. Shares of Merck have fallen 10 percent since the drugmaker several weeks ago said it would make survival a main goal of a key lung cancer trial for immunotherapy Keytruda, extending the study by up to a year. In the meantime, Roche Holding AG has shaken up Wall Street expectations for the $15-billion (£11.3 billion) lung cancer market, showing its Tecentriq immunotherapy slows the spread of advanced lung cancer when combined with older treatments.

  • Reuters5 days ago

    Roche: Tecentriq cocktail slows kidney cancer progression

    Combining Roche's Tecentriq immunotherapy with its older drug Avastin for the initial treatment of advanced kidney cancer reduced the risk of the disease worsening or of death in certain patients, the Swiss drugmaker said on Monday. The trial tested the combination against the current standard of care, Pfizer's Sutent, in patients with inoperable, locally advanced or metastatic renal cell carcinoma.

  • Reuters6 days ago

    Roche: Tecentriq cocktail slows kidney cancer progression

    Tecentriq, whose sales pale compared to established immunotherapies from Bristol-Myers Squibb and Merck & Co Inc, is a pillar of Roche's plan to replace revenue from its $20 billion-per-year trio of Avastin, Herceptin and Rituxan whose expiring patents have exposed them to cheaper competition. As a consequence, Roche is seeking to expand indications and patients eligible for treatment with its drug, which analysts see topping $4.6 billion in annual sales by 2023.

  • Reuters6 days ago

    Roche lymphoma drug drives high remission rate, longer survival-study

    An experimental Roche Holding AG drug, added to standard therapy, led to a far higher rate of remission and helped patients with an advanced, aggressive blood cancer live significantly longer than the standard treatment alone, according to data from a mid-stage trial released at a medical meeting on Sunday. In the trial of 80 patients with diffuse large B-cell lymphoma (DLBCL) whose disease had progressed despite several treatment regimens, the addition of Roche's polatuzumab vedotin raised the complete response rate to 40 percent.

  • Puma (PBYI) Stock Up More than 200% This Year: Here's Why
    Zacks8 days ago

    Puma (PBYI) Stock Up More than 200% This Year: Here's Why

    Puma's (PBYI) shares skyrocket in the year so far on the approval of its cancer drug Nerlynx in the United States coupled with strategic collaborations.

  • Roche, Novartis' Italian heads risk trial for alleged market rigging: sources
    Reuters8 days ago

    Roche, Novartis' Italian heads risk trial for alleged market rigging: sources

    Prosecutors in Rome have been looking into charges the two companies colluded to discredit eye disease drug Avastin by emphasizing its potential side effects in order to boost sales of Lucentis, a more expensive alternative which offers similar treatment. Both Avastin and Lucentis are manufactured by Roche but Lucentis is marketed by Novartis outside the United States.

  • Roche study finds cancer 'Velcro' that halts T-cell attack
    Reuters9 days ago

    Roche study finds cancer 'Velcro' that halts T-cell attack

    Scientists at Swiss drugmaker Roche said on Friday they may have discovered why some tumours resist new immunotherapy drugs as well as a possible means of turning the tables to incite a T-cell attack. The company has been analysing biomarkers in 300 patients from its Imvigour 210 bladder cancer study to learn more about those who did not respond to its Tecentriq treatment, it said at the European Society for Medical Oncology meeting in Geneva. Its doctors now believe some tumours that express high levels of a protein called TGF-beta develop a fortified wall.

  • The Wall Street Journal9 days ago

    Roche’s Immunotherapy Drug Tecentriq Extended Patients’ Lives in Study

    Roche Holding said its immunotherapy drug Tecentriq slowed the progression of lung cancer and helped patients live longer in a late-stage study, bolstering the Swiss drugmaker’s defense against a wave ...

  • Roche's Cancer Drug Combo Effective For Some — But Shares Drop
    Investor's Business Daily9 days ago

    Roche's Cancer Drug Combo Effective For Some — But Shares Drop

    Roche's Tecentriq plus older drugs doubled the percentage of lung cancer patients surviving a year without disease progression.

  • Roche Reports Tecentriq/Avastin Lung Cancer Study Data
    Zacks9 days ago

    Roche Reports Tecentriq/Avastin Lung Cancer Study Data

    Roche (RHHBY) announced interim results from the phase III IMpower150 study of Tecentriq and Avastin plus chemotherapy in people with advanced form of lung cancer.

  • Roche drug cocktail doubles chance of holding lung cancer at bay
    Reuters9 days ago

    Roche drug cocktail doubles chance of holding lung cancer at bay

    Adding Roche's immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease advancing, an outcome some experts on Thursday labelled unprecedented. Its shares retreated, however, as analysts said uncertainty lingers over whether the result is sufficient to give the Swiss drugmaker a jump on rivals Merck & Co and Bristol-Myers Squibb, whose immunotherapy sales dwarf Roche's own.

  • Reuters10 days ago

    Roche drug cocktail doubles chance of holding lung cancer at bay

    Adding Roche's immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease advancing, an outcome some experts labelled unprecedented. Thirty seven percent of patients in a closely watched clinical trial who received Tecentriq, Avastin and chemotherapy reached the one-year mark without their cancer progressing (PFS), according to data released on Thursday. For patients getting only Avastin and chemotherapy, that fell to 18 percent.

  • Clovis' sNDA for Rubraca Gets Priority Review in the U.S.
    Zacks10 days ago

    Clovis' sNDA for Rubraca Gets Priority Review in the U.S.

    The FDA grants priority review to Clovis' (CLVS) supplemental new drug application for its marketed drug, Rubraca's label expansion as a maintenance treatment for ovarian cancer.

  • Roche's Avastin Gets Full FDA Approval for Brain Cancer
    Zacks10 days ago

    Roche's Avastin Gets Full FDA Approval for Brain Cancer

    Roche (RHHBY) announced that the FDA converted accelerated approval for Avastin to full approval for the patients previously treated for aggressive form of brain cancer.

  • Roche to seize leap-frog opportunity in lung cancer
    Reuters10 days ago

    Roche to seize leap-frog opportunity in lung cancer

    After lagging rivals in cancer immunotherapies, Swiss drugmaker Roche (ROG.S) hopes to leap-frog into the lead in the biggest market, tackling previously untreated lung cancer. "We have a real chance to be at the forefront here," Chief Executive Severin Schwan said on Wednesday. At the same time he warned many investors would lose money across the industry as a large proportion of the hundreds of cancer trials now underway failed, leaving just a few winners.

  • AbbVie/J&J's Imbruvica Succeeds in Combo Study with Rituxan
    Zacks10 days ago

    AbbVie/J&J's Imbruvica Succeeds in Combo Study with Rituxan

    AbbVie (ABBV) J&J's combination study evaluating Imbruvica in Waldenstrom's macroglobulinemia (WM), a rare form of non-Hodgkin's lymphoma, meets primary endpoint.

  • Mylan Up on FDA Approval & Amazon's Rumored Pharmacy Interest
    Zacks12 days ago

    Mylan Up on FDA Approval & Amazon's Rumored Pharmacy Interest

    Mylan (MYL) receives approval for its biosimilar of breast cancer drug, Herceptin. Amazon is reportedly in talks with Mylan and another generic manufacturer about a potential entry in distribution of drugs.

  • Why Is ImmunoGen (IMGN) Stock Up More Than 150% This Year?
    Zacks19 days ago

    Why Is ImmunoGen (IMGN) Stock Up More Than 150% This Year?

    ImmunoGen's (IMGN) shares shoot up in the year so far on rapid pipeline progress plus positive study data and strategic collaborations.